Advances in targeted therapy for acute myeloid leukemia
Abstract Acute myeloid leukemia (AML) is a clonal malignancy characterized by genetic heterogeneity due to recurrent gene mutations. Treatment with cytotoxic chemotherapy has been the standard of care for more than half of a century. Although much progress has been made toward improving treatment re...
Saved in:
Main Authors: | Jifeng Yu (Author), Peter Y. Z. Jiang (Author), Hao Sun (Author), Xia Zhang (Author), Zhongxing Jiang (Author), Yingmei Li (Author), Yongping Song (Author) |
---|---|
Format: | Book |
Published: |
BMC,
2020-05-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
WITHDRAWN: SPOP Promotes Acute Myeloid Leukemia Initiation and Development Through miR-183-Mediated METAP2 Inhibition
by: Jifeng Yu, et al.
Published: (2024) -
Targeting TIGIT for cancer immunotherapy: recent advances and future directions
by: Peng Zhang, et al.
Published: (2024) -
Claudin18.2 is a novel molecular biomarker for tumor-targeted immunotherapy
by: Weijie Cao, et al.
Published: (2022) -
Single-cell map of diverse immune phenotypes in the acute myeloid leukemia microenvironment
by: Rongqun Guo, et al.
Published: (2021) -
Advances in the drug therapies of acute myeloid leukemia (except acute promyelocytic leukemia)
by: Lin M, et al.
Published: (2018)